Success of NASH Phase II Interim Analysis Explained Further
Filed with ASX · · 4 pages · English
Story so far
Earlier from Immuron
- NASH PhaseII Interim Analysis Reveals Improved Liver Enzymes
- Pre-Clinical C. difficile Infection Results Paper Published
- IMC Prices US IPO and NASDAQ Listing Raising USD$6.1M
- Travelan Increases Industry Presence - Conf & Sales Update
- Immuron Secures $1.5M R&D Cash Advance Loan Funding
Later from Immuron
- Immuron Announces Management Changes
- Immuron to Present C.difficile Data at ClostPath 2017 Confer
- Immuron Approved to Commence Clinical Study in C.Difficile
- Immuron Opens Clinical Site to Commence C.Diff CDI Study
- Appendix 4E Preliminary Final Report (30 June 2017)
Follow Immuron into a list and get an email when it puts out news.
Follow Immuron